GlaxoSmithKline – patience required

At GlaxoSmithKline’s (GSK) research and development (R&D) facility in Stevenage, employees may be concerned that the group’s increased focus on science has come too late. The major strategy shift has seen R&D investment increase 12 per cent to £2.1bn, or 14 per cent of the group’s revenue in the first half of the year.